Synthetic thyroid releasing hormone (TRH) administered orally to chronic schizophrenic patients.
Synthetic TRH and PL were administered orally for 3 weeks (300 mg./day), to long-term institutionalized chronic schizophrenic patients, within the framework of a double blind placebo controlled crossover study. Significant changes in physiological and laboratory parameters suggested increased thyroid activity, but significant favorable psychiatric and behavioral changes were not observed. This study does not support the idea that oral TRH could be useful treatment for long-term institutionalized chronic schizophrenic patients, who generally respond readily to major neuroleptic drugs.
D000284:Administration, Oral; D000328:Adult; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D010919:Placebos; D013973:Thyrotropin-Releasing Hormone